Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03505372 · ClinicalTrials.gov registry record · NA
Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia
A NA study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT03505372: Clinical Trial NA study, sponsored by Dana-Farber Cancer Institute.
NCT03505372 is a NA study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 5 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03505372, a NA study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
This research study is studying whether contrast enhanced mammography can predict if atypical ductal hyperplasia will progress to cancer. The device involved in this study is: -Contrast enhanced mammography
Primary Outcome
Investigators will evaluate whether enhancement on CESM can predict which cases of ADH upgrade at the time of surgical excision.
Interventions
- DEVICE Contrast enhanced mammography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-05-10 |
| Est. Completion | 2019-06-28 |
| Phase | NA |
Why NCT03505372 stopped before completion
NCT03505372 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Contrast enhanced mammography is the first listed.
NCT03505372 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03505372 about?
NCT03505372 is a clinical study titled "Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia". This research study is studying whether contrast enhanced mammography can predict if atypical ductal hyperplasia will progress to cancer. The device involved in this study is: -Contrast enhanced mammography
What is the current status of trial NCT03505372?
This trial is currently terminated. It is a NA study. The enrollment target is 5 participants. The study started on 2018-05-10. Estimated completion is 2019-06-28.
What interventions are being tested in trial NCT03505372?
The interventions under investigation include: Contrast enhanced mammography (DEVICE).
Who is sponsoring clinical trial NCT03505372?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03505372's enrollment target sits among peer trials
5 1988th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI